C J Rowe1,2, M H Law3, J M Palmer2, S MacGregor3, N K Hayward2, K Khosrotehrani1,4. 1. UQ Diamantina Institute, Translational Research Institute, The University of Queensland, Woolloongabba, Qld, Australia. 2. Oncogenomics, QIMR Berghofer Medical Research Institute, Herston, Qld, Australia. 3. Statistical Genetics, QIMR Berghofer Medical Research Institute, Herston, Qld, Australia. 4. The University of Queensland Centre for Clinical Research, Herston, Qld, Australia.
Abstract
BACKGROUND: A substantial number of melanoma patients will develop multiple primary melanomas (MPM). Currently, little is known about the impact of MPM on survival. OBJECTIVE: We aimed to determine whether melanoma survival is worse for patients with MPM compared to those with a single invasive primary melanoma (SPM). MATERIALS AND METHODS: A cohort study was conducted. Patients were sourced from an Australian population, with follow-up information collected retrospectively from registry data. Melanoma-specific survival analysis was performed to find associated variables after adjustment for known prognostic factors, using four different models, each selecting a different index melanoma lesion. RESULTS: 1068 stage I and II melanoma patients were followed up for a median of 24.4 years. MPM was found in 17.8% of the cohort (190 patients), more likely among males and older age groups. Other clinicopathological parameters were similar between the MPM and SPM (878 patients) cohorts. After adjustment for age, sex and Breslow thickness, MPM was a hazard for death from melanoma, across all models, reaching significance when considering the last invasive lesion as the index melanoma (HR = 2.76, P = 0.017). CONCLUSION: Patients with multiple invasive lesions seem more at risk of death from melanoma, independent of known prognostic factors.
BACKGROUND: A substantial number of melanomapatients will develop multiple primary melanomas (MPM). Currently, little is known about the impact of MPM on survival. OBJECTIVE: We aimed to determine whether melanoma survival is worse for patients with MPM compared to those with a single invasive primary melanoma (SPM). MATERIALS AND METHODS: A cohort study was conducted. Patients were sourced from an Australian population, with follow-up information collected retrospectively from registry data. Melanoma-specific survival analysis was performed to find associated variables after adjustment for known prognostic factors, using four different models, each selecting a different index melanoma lesion. RESULTS: 1068 stage I and II melanomapatients were followed up for a median of 24.4 years. MPM was found in 17.8% of the cohort (190 patients), more likely among males and older age groups. Other clinicopathological parameters were similar between the MPM and SPM (878 patients) cohorts. After adjustment for age, sex and Breslow thickness, MPM was a hazard for death from melanoma, across all models, reaching significance when considering the last invasive lesion as the index melanoma (HR = 2.76, P = 0.017). CONCLUSION:Patients with multiple invasive lesions seem more at risk of death from melanoma, independent of known prognostic factors.
Authors: Trude Eid Robsahm; Per Helsing; Yngvar Nilssen; Linda Vos; Syed Mohammad H Rizvi; Lars A Akslen; Marit B Veierød Journal: Clin Epidemiol Date: 2018-05-09 Impact factor: 4.790
Authors: Ernest Mangantig; Stuart MacGregor; Mark M Iles; Richard A Scolyer; Anne E Cust; Nicholas K Hayward; Grant W Montgomery; David L Duffy; John F Thompson; Anjali Henders; Lisa Bowdler; Casey Rowe; Gemma Cadby; Graham J Mann; David C Whiteman; Georgina V Long; Sarah V Ward; Kiarash Khosrotehrani; Jennifer H Barrett; Matthew H Law Journal: Hum Mol Genet Date: 2021-01-06 Impact factor: 6.150
Authors: Adi Nosrati; Wesley Y Yu; Joseph McGuire; Ann Griffin; Juliana Rocha de Souza; Rasnik Singh; Eleni Linos; Mary Margaret Chren; Barbara Grimes; Nicholas P Jewell; Maria L Wei Journal: J Invest Dermatol Date: 2018-07-19 Impact factor: 7.590
Authors: Annie Herbert; Minjoung M Koo; Matthew E Barclay; David C Greenberg; Gary A Abel; Nick J Levell; Georgios Lyratzopoulos Journal: Melanoma Res Date: 2020-06 Impact factor: 3.199